CA
NZ
UK
AU
IND
US
Topline data from the pivotal ECLIPSE 1 trial in chronic hepatitis delta are expected in the fourth quarter of 2026, with ECLIPSE 2 and 3 results due in the first quarter of 2027. The trials test elebsiran combined with tobevibart. Expanded Phase 2 SOLSTICE …
Gross profit rose 11.7% to USD 46.2 million, while the margin edged down because equipment and supply sales, which carry lower margins than rentals, rose to 32.0% of revenue from 30.1%. Selling, general and administrative expense was 44.0% of revenue versus 44.4%. Income from …
Key HighlightsRevenue rose 91.2% to a record USD 541.0 million in the third quarter, with organic growth of about 17% and acquisitions adding about 74 points.GAAPDiluted Earnings per Sharefrom continuing operations were USD 1.49 versus USD 0.17, and adjusted diluted earnings per share were …
The company raised the midpoints of its 2026 produced waterVolumeand adjusted EBITDA guidance by 2% and 4%. Volumes are now expected at 2.65 to 2.75 million barrels per day, and adjusted EBITDA at USD 465 million to USD 485 million.Capital Expenditureguidance was narrowed to …
Key HighlightsTotal revenues and other were USD 1,194.2 million in the third quarter, up about 25% from USD 952.5 million a year earlier (calculated), led by fee-based service revenues of USD 1,018.6 million.Net income attributable to thePartnershipwas USD 331.9 million, or USD 0.78 per …
The company announced a conditional 30-yearLoan Commitmentof USD 1.5 billion from the U.S. Department of War to support the domestic wide bandgap supply chain. Management said that, once completed, it is expected to deliver significant annual interest savings. The company lists completion of due …
GAAPOperating Incomeclimbed 71% to USD 190.8 million, a margin of 26.2% against 18.2%. The company said that expansion mainly reflects USD 39 million of tariff refunds, plus operational improvements and lower restructuring costs. Because the refunds were classified as a special item, adjusted operating …
On August 10, 2025 the company agreed to buy International Money Express, known as Intermex, for about USD 500 million in cash and to repay its revolvingCreditFacilitydebt. On August 13, 2026 New York State regulators approved the merger, but the California Department of Financial …
The company is a clinical-stage biopharmaceuticalBusinessthat engineers antibody drugs for cancer and autoimmune disease using its XmAb platforms.Research and Developmentexpense rose to USD 84.3 million from USD 54.4 million, while general and administrative expense fell to USD 9.4 million from USD 14.2 million. Operating …
On a GAAP basis, operating income turned to USD 1.8 million from a USD 1.4 million loss, and net loss narrowed to USD 5.2 million. The GAAP loss remained despite positive pretax income of USD 2.1 million because tax provision was USD 7.4 million. …
Please wait processing your request...